Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trial

Journal:

Journal of the National Cancer Institute

Published:

2025-11-21

DOI:

10.1093/jnci/djaf334

Affiliations:

19

Authors:

22

Go to article

Institutions	Authors	Share
Netherlands Cancer Institute (NKI), Netherlands	3.000000	0.14
Erasmus MC Cancer Institute, Netherlands	2.000000	0.09
Erasmus University Rotterdam (EUR), Netherlands	2.000000	0.09
Dutch Breast Cancer Research Group, Netherlands	2.000000	0.09
Netherlands Comprehensive Cancer Organisation (IKNL), Netherlands	1.000000	0.05
Spaarne Hospital, Netherlands	1.000000	0.05
Rijnstate Hospital, Netherlands	1.000000	0.05
Frisius MC, Netherlands	1.000000	0.05
Amphia Hospital, Netherlands	1.000000	0.05
Isala Clinics, Netherlands	1.000000	0.05
St. Antonius Hospital, Netherlands	1.000000	0.05
Sint Franciscus Gasthuis Rotterdam (SFG), Netherlands	1.000000	0.05
Meander Medical Centre, Netherlands	1.000000	0.05
Jeroen Bosch Ziekenhuis (JBZ), Netherlands	1.000000	0.05
Gelre Hospitals, Netherlands	1.000000	0.05
Noordwest Hospital Group, Netherlands	1.000000	0.05
Cancer Center Amsterdam (CCA), Netherlands	1.000000	0.05

Interested in Oncology and Carcinogenesis?